China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its NR-20201, an in-house developed allogeneic adipose-derived mesenchymal stromal cell-based therapy. This marks a significant step forward in the development of innovative treatments for acute ischemic stroke (AIS).
Mechanism of Action
Preclinical trial results indicate that NR-20201 can synergistically interact with vascular endothelial cells through a cell homing mechanism. This interaction activates damaged brain tissue vascular regeneration and functional repair, offering a novel approach to addressing the significant unmet needs in AIS treatment.
Global Innovation
NR-20201, which received trial approval in the US in October 2024, has no comparable product approved anywhere in the world. This positions Tasly Pharma at the forefront of innovation in cell-based therapies for neurological conditions.-Fineline Info & Tech
Leave a Reply